Shares of Omnicell, Inc. (NASDAQ:OMCL) saw unusually-high trading volume on Monday after Dougherty & Co raised their price target on the stock from $45.00 to $49.00. Dougherty & Co currently has a buy rating on the stock. Approximately 130,641 shares were traded during trading, a decline of 39% from the previous session’s volume of 215,486 shares.The stock last traded at $48.85 and had previously closed at $48.55.
Other equities research analysts have also recently issued research reports about the stock. Craig Hallum boosted their target price on shares of Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday. Cantor Fitzgerald reissued a “buy” rating and set a $47.00 target price on shares of Omnicell in a report on Tuesday, July 25th. TheStreet cut shares of Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, ValuEngine raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $49.00.
In other news, Chairman Randall A. Lipps sold 37,500 shares of the company’s stock in a transaction on Friday, July 28th. The shares were sold at an average price of $46.00, for a total value of $1,725,000.00. Following the transaction, the chairman now owns 196,551 shares of the company’s stock, valued at $9,041,346. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gary S. Petersmeyer sold 2,200 shares of the company’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $41.41, for a total transaction of $91,102.00. Following the completion of the transaction, the director now directly owns 21,075 shares in the company, valued at approximately $872,715.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 120,300 shares of company stock worth $5,199,801. Insiders own 3.77% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First National Bank of Omaha purchased a new position in Omnicell during the first quarter valued at $865,000. Renaissance Technologies LLC purchased a new position in Omnicell during the fourth quarter valued at $788,000. Parametric Portfolio Associates LLC raised its position in shares of Omnicell by 4.9% in the first quarter. Parametric Portfolio Associates LLC now owns 145,279 shares of the company’s stock valued at $5,906,000 after buying an additional 6,786 shares during the period. Bank of America Corp DE raised its position in shares of Omnicell by 79.7% in the first quarter. Bank of America Corp DE now owns 202,466 shares of the company’s stock valued at $8,231,000 after buying an additional 89,817 shares during the period. Finally, Guggenheim Capital LLC raised its position in shares of Omnicell by 75.4% in the fourth quarter. Guggenheim Capital LLC now owns 48,053 shares of the company’s stock valued at $1,628,000 after buying an additional 20,663 shares during the period. 96.35% of the stock is currently owned by hedge funds and other institutional investors.
The stock has a 50-day moving average of $43.28 and a 200 day moving average of $39.99. The company’s market capitalization is $1.82 billion.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. The company had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. Omnicell’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.38 EPS. Equities research analysts predict that Omnicell, Inc. will post $1.28 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://stocknewstimes.com/2017/07/31/omnicell-inc-nasdaqomcl-sees-strong-trading-volume-after-analyst-upgrade.html.
About Omnicell
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
